Patients who had an adverse clinical event were older, had a worse functional class and renal function, received less frequently angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) and beta-blockers, had a reduced AVA and LVEF, and had a more frequent history of COPD and heart failure than those who had not (Table 4). This evidence concerns the gene ACE and heart failure.